Objective Multiple sclerosis (MS) is a chronic autoimmune disease where B cells play a central pathogenic role. Cladribine, an oral therapy, provides durable benefits by reshaping lymphocyte populations, yet its specific long‐term impact on distinct B‐cell subsets is not fully understood.
Marta Pirronello +20 more
wiley +1 more source
Immunogenic cell death as a cornerstone for combination therapies with immune checkpoint blockade. [PDF]
Niu Y +10 more
europepmc +1 more source
A multi-epitope vaccine targeting a key virulence factor ClfA: An In-silico approach to combat Staphylococcus aureus infections. [PDF]
Nirob MNH +8 more
europepmc +1 more source
Hemophagocytic lymphohistiocytosis as the initial manifestation of Epstein-Barr virus-related T/NK-cell lymphoproliferative disorders in a pediatric patient: a case report and literature review. [PDF]
Ma L, Xing X, Liu Y, Jiang W.
europepmc +1 more source
Cellular immunotherapy in melanoma: the next frontier in cancer treatment. [PDF]
Wien AL, Stamtsis-Datsi A.
europepmc +1 more source
Bronchus-associated lymphoid tissue: a review of its development and function, including recent findings on the impact of environmental particulate exposure. [PDF]
Mikami Y +10 more
europepmc +1 more source
The Role of CD4<sup>+</sup> T Helper Cell Subsets in Hepatocellular Carcinoma: Implications for Tumour Progression and Immunotherapy. [PDF]
Shao J +7 more
europepmc +1 more source
Chemoattractant lymphokines specific for the helper/inducer T-lymphocyte subset
The cellular content of T-lymphocyte-rich inflammatory sites is dependent in part on the in situ elaboration of chemoattractant factors. We have previously described three T-lymphocyte-specific chemoattractant lymphokines; a chemokinetic factor, lymphocyte chemoattractant factor (LCF, MW 56,000), and two distinct lymphocyte migration inhibitory factors
J S, Berman +4 more
openaire +3 more sources

